Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable?

Mundo, Emanuela; Bareggi, Silvio R.; Pirola, Romano C.; Bellodi, Laura

doi:10.1016/s0006-3223(98)00027-4

Cited by 63 publications

(33 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In accordance with this, there is some support that females are more likely to drop out from TCA treatment, whereas males are more likely to drop out from SSRI treatment [52]. One study treating male and female OCD patients with either a TCA or an SSRI found no significant sex differences in drop-out rates [54]. However, as 46% of males compared to 29% of females failed to complete the treatment, it is possible that the lack of significant sex differences were due to low power.…”

Section: Pharmacotherapymentioning

confidence: 80%

“…A study of OCD patients found that females responded better to treatment with either the TCA clomipramine or the SSRI flovixamine than males [54]. However, due to an already small sample size and high drop-out rates, it is unclear whether these differences were equal for the two drugs and whether interactions between treatment and response to a prior symptom-provoking agent differed for males and females.…”

Section: Pharmacotherapymentioning

confidence: 99%

See 1 more Smart Citation

Examining Sex and Gender Differences in Anxiety Disorders

Christiansen¹

2015

A Fresh Look at Anxiety Disorders

View full text Add to dashboard Cite

Several studies have examined sex differences in different anxiety disorders. Females are repeatedly found to be more likely than males to suffer from anxiety in general and to be diagnosed with most anxiety disorders, including agoraphobia (AG), panic disorder (PD), separation anxiety (SA), specific phobia (SP), social anxiety disorder (SAD), generalised anxiety disorder (GAD), obsessive-compulsive disorder (OCD), and acute and posttraumatic stress disorder (ASD and PTSD), although the latter three are technically no longer categorised as anxiety disorders according to DSM-5. This chapter provides an overview of research on sex and gender differences in anxiety disorders ranging from the well-established female preponderance in prevalence and severity to possible sex differences in the risk and protective factors associated with anxiety, sex differences in the clinical presentation of anxiety disorders, and potential sex differences in the effectiveness of different treatments. The chapter contains suggestions for future research, including important questions that remain to be answered.

show abstract

Section: Pharmacotherapymentioning

confidence: 80%

Section: Pharmacotherapymentioning

confidence: 99%

Examining Sex and Gender Differences in Anxiety Disorders

Christiansen¹

2015

A Fresh Look at Anxiety Disorders

View full text Add to dashboard Cite

show abstract

“…Gender differences in the efficacy of serotoninergic acting drugs have recently been found for the treatment of obsessive compulsive disorder, with women responding better to clomipramine and fluoxetine compared to men (Mundo et al, 1999). Similarly, women treated for depression respond less well to tricyclic antidepressants and better to SSRIs and MAO inhibitors (Kornstein, 1997;Kornstein et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

State Markers of Depression in Sleep EEG: Dependency on Drug and Gender in Patients Treated with Tianeptine or Paroxetine

Murck

Nickel

Künzel

et al. 2003

Neuropsychopharmacol

View full text Add to dashboard Cite

Tianeptine enhances while paroxetine inhibits serotonin reuptake into neurons; however, both show an antidepressive action. A subgroup of 38 depressed patients from a drug trial comparing the efficacy of tianeptine with that of paroxetine was studied with regard to their effects on sleep regulation, especially in relation to treatment response. We recorded sleep EEGs at day 7 and day 42 after the start of treatment with either compound, which allows measurement of changes due to the antidepressive medication in relation to the duration of treatment. Spectral analysis of the non-REM sleep EEG revealed a strong decline in the higher sigma frequency range (14-16 Hz) in male treatment responders independent of medication, whereas nonresponders did not show marked changes in this frequency range independent of gender. The patients receiving paroxetine showed less REM sleep and more intermittent wakefulness compared to the patients receiving tianeptine. REM density after 1 week of treatment was a predictor of treatment response in the whole sample. Psychopathological features with regard to the score in single items of the HAMD revealed predictive markers for response, some of which were opposite in the gender groups, especially those related to somatic anxiety. Changes in REM density were inversely correlated to the changes in HAMD in the paroxetine, but not the tianeptine, group. Our data suggest the importance of taking gender into account in the study of the biological effects of drugs. The study further points to the importance of the higher sigma frequency range in the sleep EEG of non-REM sleep and REM density as a marker of treatment response.

show abstract

“…Several studies have reported sex-related differences in the clinical manifestations of OCD, including an earlier age at onset for male patients, [55][56][57][58] more cleaning obsessions and contamination compulsions in female patients and symmetry/ ordering symptoms in male patients, [58][59][60] and sex differences in response to OCD treatment. 61 Moreover a sex-specific contribution to OCD susceptibility has also been reported for other candidate genes, such as MAO and COMT. 58 …”

mentioning

confidence: 87%

Association between the NMDA glutamate receptor GRIN2B gene and obsessive–compulsive disorder

Alonso

Gratacòs

Segalás

et al. 2012

jpn

View full text Add to dashboard Cite

Background: Recent data from neuroimaging, genetic and clinical trials and animal models suggest a role for altered glutamatergic neuro transmission in the pathogenesis of obsessive-compulsive disorder (OCD). The aim of this study was to investigate whether variants in the GRIN2B gene, the gene encoding the NR2 subunit of the N-methyl-D-aspartate (NMDA) glutamate receptor, may contribute to genetic susceptibility to OCD or to different OCD subphenotypes. Methods: Between 2003 and 2008, we performed a case-control association study in which we genotyped 10 tag single-nucleotide polymorphisms (SNPs) in the 3′ untranslated region (3′ UTR) of GRIN2B. We performed SNP association and haplotype analysis considering the OCD diagnosis and different OCD subphenotypes: early-onset OCD, comorbid tic disorders and OCD clinical symptom dimensions. Results: We enrolled 225 patients with OCD and 279 controls recruited from the OCD Clinic at Bellvitge Hospital (Barcelona, Spain). No significant difference in the distribution of alleles or genotypes was detected between patients with OCD and controls. Nonetheless, on analyzing OCD subphenotypes, the rs1805476 SNP in male patients (95% confidence interval [CI] 1.37-4.22, p = 0.002) and a 4-SNP haplotype in the whole sample (rs1805476, rs1805501, rs1805502 and rs1805477; odds ratio 1.92, 95% CI 1.22-3.01; permutation p = 0.023) were significantly associated with the presence of contamination obsessions and cleaning compulsions. Limitations: Study limitations included the risk of population stratification associated with the case-control design, use of psychiatrically unscreened blood donors as the control group, reduced sample size of participants with certain OCD subphenotypes and tested polymorphisms limited to 3′ UTR and exon 13 of GRIN2B. Conclusion: Our results converge with recent data suggesting a possible contribution of glutamatergic variants to the genetic vulnerability to OCD or at least to certain OCD manifestations. The dissection of OCD into more homogeneous subphenotypes may constitute a useful tool to disentangle the complex genetic basis of the disorder.

show abstract

Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable?

Cited by 63 publications

References 13 publications

Examining Sex and Gender Differences in Anxiety Disorders

Examining Sex and Gender Differences in Anxiety Disorders

State Markers of Depression in Sleep EEG: Dependency on Drug and Gender in Patients Treated with Tianeptine or Paroxetine

Association between the NMDA glutamate receptor GRIN2B gene and obsessive–compulsive disorder

Contact Info

Product

Resources

About